Clinically proven to support cognitive function, vitality, and healthy aging in dogs, starting with their cells.

Play Video about Leap Years Cellular Health Supplement Clinical Trial
9 out of 10 dogs' cognition improved or remained stable


Old dogs have a lot of complexities associated with cognitive decline with age. Dogs had to have mild or moderate cognitive dysfunction to be included in the trial. (Schutt, 2015; Salvin, 2011) Dogs who were administered Leap Years showed improved or stable cognition at 90 days (statistically significant difference compared with placebo controls). The anticipated deterioration of age-related cognitive function in these old dogs was delayed.

3 out of 4 dogs showed no increase in frailty


Five domains made up the frailty score: unintentional weight loss/body condition score, gait abnormalities, exhaustion, weakness/muscle loss (atropy/cachexia) and social activity. (Russel, 2022) A dog was graded as more frail if three of five were recorded. Three out of four dogs receiving Leap Years showed no increase in frailty over 90 days.

100% of dogs improved or maintained their happiness


Happiness was assessed by pet parents as worse, the same or better compared to the previously made assessments in the study. (Adrian, 2021) The score took into account the level of engagement by the dog. 100% of dogs receiving Leap Years were graded as happy or happier at each assessment timepoint. Several pet parents reported “zoomies” like when the dog was younger.

2x as many dogs showed improved activity vs. placebo


Pet parents reported improvement in activity for twice as many dogs in the Leap Years group compared with the placebo group. This qualitative measure captured the nuances observed by the pet parent regarding the amount of activity the dogs had over the 90 days compared with baseline.


Schutt T, Toft N, Berendt M. Cognitive function and progression of age-related behavior changes, biomarkers and survival in dogs more than 8 years old. J Vet Int Med 2015; 1569-1577

Salvin HE, McGreevy PD, Sachdev SP, Valenzuela MJ. The canine cognitive dysfunction rating scale (CCDR): A data-driven and ecologically relevant assessment tool. Vet J 2011: (188) 331-336

Adrian D, King JN, Parrish RS, Budsberg SC, Gruen MS, Lascelles BDX. Robenacoxib shows efficacy for the treatment of chronic degenerative joint disease-associated pain in cats: a randomized and blinded pilot clinical trial. Scientific Reports 2021; 11:7721

Russel K. Establishing a Frailty Phenotype for Aging Dogs JVIM 2022 vol 36-p2289

May, 2024

Clinical Trial Publication

A double blind, placebo controlled clinical trial with Leap Years was conducted at North Carolina State University College of Veterinary Medicine.

"The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement. This rigorous study, which acknowledges the difficulties aging pets and their owners encounter, shows dedication to scientific methods aimed at improving the quality of life for our canine companions.”


  - Natasha Olby Vet MB, PhD, DACVIM (Neuro)

Hear From Clinical Trial Participants

Play Video

How Leap Years Slows the Effects of Aging

Play Video
Our Chief Veterinary Officer, Ginny Rentko, VMD, DACVIM, explains how Leap Years works and what makes it different from other dog supplements.

Leap Years
Veterinarian Developed,
Paw Approved

Leap Years was developed over five years by our veterinary team to understand its effects, specifically in dogs, to address the root causes of aging, starting at the cellular level.

Are You A Veterinarian?

Hear from Dr. Heather Oxford on Why She Recommends Leap Years®

Play Video
Interested in becoming a veterinary partner? Start addressing the effects of aging today.
Shopping Cart
Scroll to Top

Special Offer For Your Dog

Enter at checkout